Cargando…
Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases. This review derives the structural complementarity of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051736/ https://www.ncbi.nlm.nih.gov/pubmed/36986499 http://dx.doi.org/10.3390/ph16030400 |
_version_ | 1785014961215373312 |
---|---|
author | Najmi, Asim Thangavel, Neelaveni Mohanan, Anugeetha Thacheril Qadri, Marwa Albratty, Mohammed Ashraf, Safeena Eranhiyil Saleh, Safaa Fathy Nayeem, Maryam Mohan, Syam |
author_facet | Najmi, Asim Thangavel, Neelaveni Mohanan, Anugeetha Thacheril Qadri, Marwa Albratty, Mohammed Ashraf, Safeena Eranhiyil Saleh, Safaa Fathy Nayeem, Maryam Mohan, Syam |
author_sort | Najmi, Asim |
collection | PubMed |
description | Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases. This review derives the structural complementarity of the BTK-kinase domain and its inhibitors from recent three-dimensional structures of inhibitor-bound BTK in the protein data bank (PDB). Additionally, this review analyzes BTK-mediated effector responses of B-cell development and antibody production. Covalent inhibitors contain an α, β-unsaturated carbonyl moiety that forms a covalent bond with Cys481, stabilizing αC-helix in inactive-out conformation which inhibits Tyr551 autophosphorylation. Asn484, located two carbons far from Cys481, influences the stability of the BTK-transition complex. Non-covalent inhibitors engage the BTK-kinase domain through an induced-fit mechanism independent of Cys481 interaction and bind to Tyr551 in the activation kink resulting in H3 cleft, determining BTK selectivity. Covalent and non-covalent binding to the kinase domain of BTK shall induce conformational changes in other domains; therefore, investigating the whole-length BTK conformation is necessary to comprehend BTK’s autophosphorylation inhibition. Knowledge about the structural complementarity of BTK and its inhibitors supports the optimization of existing drugs and the discovery of drugs for implication in B-cell malignancies and autoimmune diseases. |
format | Online Article Text |
id | pubmed-10051736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100517362023-03-30 Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases Najmi, Asim Thangavel, Neelaveni Mohanan, Anugeetha Thacheril Qadri, Marwa Albratty, Mohammed Ashraf, Safeena Eranhiyil Saleh, Safaa Fathy Nayeem, Maryam Mohan, Syam Pharmaceuticals (Basel) Review Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases. This review derives the structural complementarity of the BTK-kinase domain and its inhibitors from recent three-dimensional structures of inhibitor-bound BTK in the protein data bank (PDB). Additionally, this review analyzes BTK-mediated effector responses of B-cell development and antibody production. Covalent inhibitors contain an α, β-unsaturated carbonyl moiety that forms a covalent bond with Cys481, stabilizing αC-helix in inactive-out conformation which inhibits Tyr551 autophosphorylation. Asn484, located two carbons far from Cys481, influences the stability of the BTK-transition complex. Non-covalent inhibitors engage the BTK-kinase domain through an induced-fit mechanism independent of Cys481 interaction and bind to Tyr551 in the activation kink resulting in H3 cleft, determining BTK selectivity. Covalent and non-covalent binding to the kinase domain of BTK shall induce conformational changes in other domains; therefore, investigating the whole-length BTK conformation is necessary to comprehend BTK’s autophosphorylation inhibition. Knowledge about the structural complementarity of BTK and its inhibitors supports the optimization of existing drugs and the discovery of drugs for implication in B-cell malignancies and autoimmune diseases. MDPI 2023-03-07 /pmc/articles/PMC10051736/ /pubmed/36986499 http://dx.doi.org/10.3390/ph16030400 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Najmi, Asim Thangavel, Neelaveni Mohanan, Anugeetha Thacheril Qadri, Marwa Albratty, Mohammed Ashraf, Safeena Eranhiyil Saleh, Safaa Fathy Nayeem, Maryam Mohan, Syam Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases |
title | Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases |
title_full | Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases |
title_fullStr | Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases |
title_full_unstemmed | Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases |
title_short | Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases |
title_sort | structural complementarity of bruton’s tyrosine kinase and its inhibitors for implication in b-cell malignancies and autoimmune diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051736/ https://www.ncbi.nlm.nih.gov/pubmed/36986499 http://dx.doi.org/10.3390/ph16030400 |
work_keys_str_mv | AT najmiasim structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT thangavelneelaveni structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT mohanananugeethathacheril structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT qadrimarwa structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT albrattymohammed structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT ashrafsafeenaeranhiyil structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT salehsafaafathy structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT nayeemmaryam structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases AT mohansyam structuralcomplementarityofbrutonstyrosinekinaseanditsinhibitorsforimplicationinbcellmalignanciesandautoimmunediseases |